While low ALDH2 activity increases cellular susceptibility to AcAH toxicity, it may paradoxically confer malignant potential and survival advantage to tumor cells under drug pressure, suggesting that restoring ALDH2 activity could be a potential therapeutic strategy in melanoma patients undergoing targeted therapy. The gene discussed is ALDH2; the disease is neoplasm.